First Manhattan
MDGL icon

First Manhattan’s Madrigal Pharmaceuticals MDGL Stock Holding History

First Manhattan’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2
Closed – – 1433
2017
Q1 		$0 Hold
2
– – ﹤0.01% 1425
2016
Q4 		$0 Buy
+2
New +$32 ﹤0.01% 1412
2016
Q3 		– Sell
-3
Closed – – 1432
2016
Q2 		$0 Hold
3
– – ﹤0.01% 1496
2016
Q1 		$0 Buy
+3
New +$25 ﹤0.01% 1431

Other funds holding MDGL

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Manhattan's MDGL Position: Q2 2017 in Review

First Manhattan sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2017, closing a stake of 2 shares.

First Manhattan first reported a position in MDGL in Q1 2016 and held it in 4 quarters. The position peaked at $0 in Q1 2017. 42 funds tracked by Wall St. Rank hold MDGL as of Q2 2017.

  • First Manhattan reported no remaining Madrigal Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • First Manhattan sold 2 Madrigal Pharmaceuticals shares in Q2 2017.
  • First Manhattan first reported a position in Madrigal Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • First Manhattan's Madrigal Pharmaceuticals position peaked at $0 in Q1 2017.
  • 42 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2017.

Based on First Manhattan's 13F filing for Q2 2017, filed 28 Jul 2017.